Inhibition of hepatic azo-reductase and aromatic hydroxylase by radiopharmaceuticals containing tin.
Mice given single i.v. doses of some radiopharmaceuticals containing stannous chloride as a reducing agent, showed significant inhibition of hepatic azo-reductase and aromatic hydroxylase activity at dose levels which contained as little as 0.2 mg/kg of stannous chloride. Cytochrome P-450 content was also reduced significantly. Some of the above radiopharmaceuticals would have to be injected at approx. 10 times the maximum recommended human dose to reach a 0.2 mg/kg dose level of stannous chloride in man, provided other sources of stannous ion were excluded.
D000815:Aniline Hydroxylase / Q000037:antagonists & inhibitors*; D000818:Animals; D001189:Aryl Hydrocarbon Hydroxylases / Q000037:antagonists & inhibitors*; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D008099:Liver / Q000201:enzymology*; D008297:Male; D051379:Mice; D009247:NADH, NADPH Oxidoreductases / Q000037:antagonists & inhibitors*; D009601:Nitroreductases; D014001:Tin / Q000494:pharmacology*; D017971:Tin Compounds
D017971:Tin Compounds; C023599:stannous chloride; D014001:Tin; D003577:Cytochrome P-450 Enzyme System; D000815:Aniline Hydroxylase; D001189:Aryl Hydrocarbon Hydroxylases; D009247:NADH, NADPH Oxidoreductases; D009601:Nitroreductases; C021106:azoreductase